Verification register Bio, Health & Neuro
Current reading
The readiness gap, in one scan
AI-assisted assembly · derived results
- Claimed
- 45
- Reported
- 45
- Verified
- 42
- Gap
- +3
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed minus verified
Evidence strength Strong
Decision
What the current evidence supports
Human editorial judgment · 2026-06-28
Track; not yet
- Why
- Being clinical-stage (oral small molecule, dosed in 2025) and well-capitalized at a $1.8B valuation puts RTR242 ahead of the reprogramming candidates on maturity, but the core autophagy-aging hypothesis remains unvalidated in humans and disclosure is limited
- Next
- Watch for the RTR242 Phase 1 safety/biomarker readout and the additional 2026/2027 first-in-human milestones; reassess once an autophagy-engagement biomarker translates to a clinical signal
Constraints
Blockers
No named blocker is present in the current public projection.
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 6
- Tier 1
- 1
- Tier 2
- 3
- Tier 3
- 2
- Supports
- 3
- Contradicts
- 1
- Context
- 2
- Latest observed
- 2026-05-23
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Initial public reading
This is the initial public reading. No earlier readiness change is recorded.